AU2005280975B2 - Anti-A33 antibody - Google Patents

Anti-A33 antibody Download PDF

Info

Publication number
AU2005280975B2
AU2005280975B2 AU2005280975A AU2005280975A AU2005280975B2 AU 2005280975 B2 AU2005280975 B2 AU 2005280975B2 AU 2005280975 A AU2005280975 A AU 2005280975A AU 2005280975 A AU2005280975 A AU 2005280975A AU 2005280975 B2 AU2005280975 B2 AU 2005280975B2
Authority
AU
Australia
Prior art keywords
antibody
seq
variable region
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005280975A
Other languages
English (en)
Other versions
AU2005280975A1 (en
Inventor
Shiro Kataoka
Noriko Otani
Takafumi Tomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of AU2005280975A1 publication Critical patent/AU2005280975A1/en
Assigned to KIRIN HOLDINGS KABUSHIKI KAISHA reassignment KIRIN HOLDINGS KABUSHIKI KAISHA Request for Assignment Assignors: KIRIN BEER KABUSHIKI KAISHA
Assigned to KIRIN PHARMA KABUSHIKI KAISHA reassignment KIRIN PHARMA KABUSHIKI KAISHA Request for Assignment Assignors: KIRIN HOLDINGS KABUSHIKI KAISHA
Assigned to KYOWA HAKKO KIRIN CO., LTD. reassignment KYOWA HAKKO KIRIN CO., LTD. Request for Assignment Assignors: KIRIN PHARMA KABUSHIKI KAISHA
Application granted granted Critical
Publication of AU2005280975B2 publication Critical patent/AU2005280975B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2005280975A 2004-09-06 2005-09-02 Anti-A33 antibody Ceased AU2005280975B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004-259090 2004-09-06
JP2004259090 2004-09-06
PCT/JP2005/016576 WO2006028197A1 (fr) 2004-09-06 2005-09-02 Anticorps anti-a33

Publications (2)

Publication Number Publication Date
AU2005280975A1 AU2005280975A1 (en) 2006-03-16
AU2005280975B2 true AU2005280975B2 (en) 2009-06-18

Family

ID=36036478

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005280975A Ceased AU2005280975B2 (en) 2004-09-06 2005-09-02 Anti-A33 antibody

Country Status (10)

Country Link
US (2) US7579187B2 (fr)
EP (2) EP1801208A4 (fr)
JP (2) JP4088655B2 (fr)
KR (1) KR100918746B1 (fr)
CN (1) CN101010427B (fr)
AU (1) AU2005280975B2 (fr)
CA (1) CA2579391C (fr)
HK (1) HK1105993A1 (fr)
TW (1) TW200621803A (fr)
WO (1) WO2006028197A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667067A1 (fr) * 2006-10-19 2008-04-24 Merck & Co., Inc. Antagonistes d'anticorps du recepteur a1 de l'interleukine-13
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
NZ584911A (en) 2007-11-02 2011-08-26 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
ES2445755T3 (es) * 2007-11-07 2014-03-05 Celldex Therapeutics, Inc. Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
MX2010014319A (es) 2008-07-08 2011-05-19 Geneuro Sa Uso terapeutico de ligando especifico en enfermedades asociadas con msrv.
EP2917236A2 (fr) * 2012-11-06 2015-09-16 MedImmune, LLC Polythérapies à l'aide de molécules de liaison anti-pseudomonas psl et pcrv
AU2013370171B2 (en) * 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
EP2777714A1 (fr) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Procédé de production d'un conjugué de ligand immunologique/charge utile à l'aide d'une enzyme transpeptidase spécifique pour une séquence
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CN110540591A (zh) * 2019-08-09 2019-12-06 无锡傲锐东源生物科技有限公司 一种抗糖蛋白A33（Glycoprotein A33）单克隆抗体及其免疫检测应用
US20240026037A1 (en) * 2020-11-18 2024-01-25 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199141A2 (fr) * 1985-04-19 1986-10-29 Sloan-Kettering Institute For Cancer Research Anticorps monoclonaux contre le cancer gastro-intestinal humain
US20020199213A1 (en) * 2000-11-30 2002-12-26 Kirin Beer Kabushiki Kaisha Transgenic transchromosomal rodents for making human antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5851526A (en) * 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5160723A (en) 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5431897A (en) * 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE214734T1 (de) * 1992-12-10 2002-04-15 Celltech Therapeutics Ltd Gegen das a33 antigen gerichtete humanisierte antikörper
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
US6643550B2 (en) * 2000-12-15 2003-11-04 Cardiac Pacemakers, Inc. Multi-polar connector
JP2004259090A (ja) 2003-02-27 2004-09-16 Toshiba Corp 情報処理装置および情報処理方法
US7432359B2 (en) * 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
JP4976741B2 (ja) * 2006-05-16 2012-07-18 株式会社東芝 平面アンテナ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199141A2 (fr) * 1985-04-19 1986-10-29 Sloan-Kettering Institute For Cancer Research Anticorps monoclonaux contre le cancer gastro-intestinal humain
US20020199213A1 (en) * 2000-11-30 2002-12-26 Kirin Beer Kabushiki Kaisha Transgenic transchromosomal rodents for making human antibodies

Also Published As

Publication number Publication date
HK1105993A1 (en) 2008-02-29
EP1801208A4 (fr) 2009-04-01
EP1801208A1 (fr) 2007-06-27
US20090299039A1 (en) 2009-12-03
CN101010427A (zh) 2007-08-01
US20070141054A1 (en) 2007-06-21
TWI359154B (fr) 2012-03-01
CN101010427B (zh) 2011-07-27
CA2579391C (fr) 2010-10-26
AU2005280975A1 (en) 2006-03-16
EP2145954A1 (fr) 2010-01-20
WO2006028197A1 (fr) 2006-03-16
JP4088655B2 (ja) 2008-05-21
US7579187B2 (en) 2009-08-25
TW200621803A (en) 2006-07-01
KR100918746B1 (ko) 2009-09-24
CA2579391A1 (fr) 2006-03-16
KR20070088570A (ko) 2007-08-29
JP2008138004A (ja) 2008-06-19
JPWO2006028197A1 (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
AU2005280975B2 (en) Anti-A33 antibody
CN101124240B (zh) 肝细胞生长因子的特异性结合物
KR101585990B1 (ko) 암 치료를 위한 ｃｌａｕｄｉｎ-18에 대한 모노클로날 항체
CA2501984C (fr) Anticorps se liant au recepteur de l'erythropoietine
CA2648618C (fr) Nouvel anticorps anti-cd98
US20040175379A1 (en) Erythropoietin receptor binding antibodies
KR20080090403A (ko) 암 치료를 위한 클라우딘-18에 대한 모노클로날 항체
CZ20021760A3 (cs) Použití anti-CTLA-4 protilátek
TW201008579A (en) Anti-Fn14 antibodies and uses thereof
US7432359B2 (en) Anti-A33 antibody
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
AU2020316495A1 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
KR20220071177A (ko) 인간화 항-vegf 단클론 항체
AU2023208150A1 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
CN113226371A (zh) 与TfR结合的双特异性抗体
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
RU2810756C2 (ru) Биспецифические антитела, связывающиеся с tfr
RU2812280C1 (ru) Связывающиеся с pd-1 антитела и способы их применения
CN117580861A (zh) 用抗icos抗体治疗pd-l1阴性或低表达癌症
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
CN117460529A (zh) 抗icos抗体的用途
KR20200014436A (ko) 클라우딘 6을 발현하는 암 치료용 항체

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: KIRIN HOLDINGS KABUSHIKI KAISHA

Free format text: FORMER NAME: KIRIN BEER KABUSHIKI KAISHA

PC1 Assignment before grant (sect. 113)

Owner name: KIRIN PHARMA KABUSHIKI KAISHA

Free format text: FORMER APPLICANT(S): KIRIN HOLDINGS KABUSHIKI KAISHA

PC1 Assignment before grant (sect. 113)

Owner name: KYOWA HAKKO KIRIN CO., LTD.

Free format text: FORMER APPLICANT(S): KIRIN PHARMA KABUSHIKI KAISHA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired